The SHIGETEVAX partner and vaccine inventor Eveliqure Biotechnologies announces the publication of key pre-clinical data of their Shigella and ETEC combination vaccine candidate.
ShigETEC is a live attenuated vaccine candidate developed by Eveliqure Biotechnologies GmbH (Austria) aimed at protecting against Shigella and ETEC infections. A manuscript describing the pre-clinical ShigETEC vaccine development has been published in the peer-reviewed journal Vaccines MDPI. Data included in the manuscript demonstrate that ShigETEC vaccination results in broad protection against different Shigella serotypes/species in mice. This is attributed to the removal of the immunodominant and serotype determining LPS O-antigen by genetic modification of the vaccine strain. The ETEC coverage is achieved by expressing non-toxigenic ETEC toxoids by the Shigella vaccine strain. ShigETEC is non-invasive and avirulent, and therefore expected to address the reactogenicity problem experienced in clinical studies with previous generations of live Shigella vaccines. ShigETEC vaccine safety and immunogenicity are being evaluated in a Phase 1 clinical trial as part of the SHIGETECVAX project.
To read the Eveliqure press release please click here: https://dd0878df-7f1d-4cd4-99b5-1a0d62bc3ecf.filesusr.com/ugd/f57d6c_6d73f349ee024f7ea02b49cb303086cf.pdf
To download the full publication, please click here: https://www.mdpi.com/2076-393X/8/4/689/pdf
Comments